Stock DNA
Pharmaceuticals & Biotechnology
SEK 1,384 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-0.10
-11.60%
0.76
Revenue and Profits:
Net Sales:
324 Million
(Quarterly Results - Jun 2025)
Net Profit:
-182 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-50.43%
0%
-50.43%
6 Months
-39.77%
0%
-39.77%
1 Year
-57.7%
0%
-57.7%
2 Years
-49.05%
0%
-49.05%
3 Years
-81.47%
0%
-81.47%
4 Years
-95.14%
0%
-95.14%
5 Years
-85.58%
0%
-85.58%
BICO Group AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
64.94%
EBIT Growth (5y)
-214.15%
EBIT to Interest (avg)
-2.40
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.18
Sales to Capital Employed (avg)
0.44
Tax Ratio
2.33%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
1.56%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.67
EV to EBIT
-8.32
EV to EBITDA
34.60
EV to Capital Employed
0.73
EV to Sales
1.21
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-8.72%
ROE (Latest)
-16.27%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 2 Foreign Institutions (1.56%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
324.20
534.00
-39.29%
Operating Profit (PBDIT) excl Other Income
-64.60
29.10
-321.99%
Interest
77.20
43.80
76.26%
Exceptional Items
-2.80
-7.10
60.56%
Consolidate Net Profit
-181.70
-78.70
-130.88%
Operating Profit Margin (Excl OI)
-335.30%
-105.60%
-22.97%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -39.29% vs -1.31% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -130.88% vs 91.24% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,946.30
2,010.40
-3.19%
Operating Profit (PBDIT) excl Other Income
102.90
36.00
185.83%
Interest
97.90
95.90
2.09%
Exceptional Items
-27.60
-319.40
91.36%
Consolidate Net Profit
-93.70
-788.70
88.12%
Operating Profit Margin (Excl OI)
-157.90%
-150.90%
-0.70%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -3.19% vs -5.21% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 88.12% vs -1,652.67% in Dec 2023
About BICO Group AB 
BICO Group AB
Pharmaceuticals & Biotechnology
Cellink AB is a Sweden-based company, which is primarily involved in the healthcare industry. The Company operates as a provider of advanced bioprinting solutions for healthcare sector. The Company offers 3D bioprinting of human tissues and organs. The Company's technology facilitates the biofabrication of cell-laden anatomical structures with controlled cell density and homogenous distribution of viable cells. The cell-laden bioink structures are then cultured in vitro, under controlled conditions for a wide range of experiments. In addition, bioprinting with human cells can be combined with computer-aided design (CAD) and computer-aided manufacturing (CAM) using medical images from CT or MRI scans to create a blueprint (3D model) for bioprinting of patient-specific tissues and organs.
Company Coordinates 
Company Details
Arvid Wallgrens Backe 20 , GOETEBORG None : 413 46
Registrar Details






